Research ArticleClinical Studies

Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series

HIROSHI AOKI, NAOKI MATSUMOTO, HIROSHI TAKAHASHI, MASAYUKI HONDA, TOMOHIRO KANEKO, SHUHEI ARIMA, TOMOTAKA ISHII, TAKU MIZUTANI, RYOTA MASUZAKI, KAZUSHIGE NIREI, HIROAKI YAMAGAMI, MASAHIRO OGAWA, TATSUO KANDA, MITSUHIKO MORIYAMA and KATSUHIRO MIURA
Anticancer Research December 2021, 41 (12) 6225-6230; DOI: https://doi.org/10.21873/anticanres.15442

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series
HIROSHI AOKI, NAOKI MATSUMOTO, HIROSHI TAKAHASHI, MASAYUKI HONDA, TOMOHIRO KANEKO, SHUHEI ARIMA, TOMOTAKA ISHII, TAKU MIZUTANI, RYOTA MASUZAKI, KAZUSHIGE NIREI, HIROAKI YAMAGAMI, MASAHIRO OGAWA, TATSUO KANDA, MITSUHIKO MORIYAMA, KATSUHIRO MIURA
Anticancer Research Dec 2021, 41 (12) 6225-6230; DOI: 10.21873/anticanres.15442
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords